The board of directors of the Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. announced that, the Company has received the Acceptance Notice issued by the National Medical Products Administration of the PRC (the NMPA). The application for confirmatory clinical trial of aminolevulinic acid hydrochloride granules (the Drug) for visualization of non-muscular invasive bladder cancer during transurethral resection of bladder tumor has been accepted. Relevant information is as follows: About the Drug: Drug name: Aminolevulinic acid hydrochloride granules; Registration type: Chemical drug, class 3 generic drug; Application matter: Registration of Clinical Trial of Domestic Production of Pharmaceutical Product; Acceptance No.

CYHL2300154; Applicant: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd; Review conclusion: Accepted upon review according to the requirements of Article 32 of the Administrative License Law of the People's Republic of China.